Results - Announcements
Aarti Pharmalabs Ltd share price slipped 0.59% to Rs 879.7 after the company's net profit slipped by 6.13% to Rs 71.47 crore, while revenue from operations edged up 13.93% to Rs 610.45 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.30%. It has inched up 3.87% over last one week and gained upto 0.06% in last one month while the market capitalization of Aarti Pharmalabs Ltd has marginally improved by 6.11% and 31.70% in the same period respectively.
Profit before tax (PBT) of Aarti Pharmalabs Ltd stood at Rs 94.99 crore in Q3 FY26, surging by 145.52% year-on-year, and slipping 6.01% quarter-on-quarter. EBITDA came in at Rs 135 crore, expanding by 80.38% YoY and declining 0.72% sequentially.
Total expenses went up by 17.71% to Rs 505.82 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 334.88 crore, soaring by 32.96% YoY, while employee benefits expense was at Rs 54.55 crore, improving by 8.41% YoY.
For the TTM ended FY26, revenue from operations declined by 13.98% to Rs 1819.44 crore, while net profit plunged by 35.86% to Rs 174.71 crore, compared to previous TTM. EBITDA soared by 47069% to Rs 359.46 crore, and PBT tanked by 35.42% to Rs 232.92 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 261.93 crore in FY26, as against Rs 330.14 crore in FY25.
Aarti Pharmalabs Ltd gained 4.29% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.45% during the same period.
